41270-69-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Phenylpyrazin-2-amine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Research and Development:
In the field of scientific research, 6-Phenylpyrazin-2-amine is used as a starting material for the synthesis of novel compounds with potential applications in various areas, such as medicinal chemistry, material science, and agrochemistry. Its versatility in chemical reactions makes it a valuable asset in the discovery of new molecules with specific properties.
Used in Industrial Applications:
6-Phenylpyrazin-2-amine can be employed in the production of specialty chemicals, such as dyes, pigments, and other organic compounds used in various industries. Its ability to form a wide range of derivatives makes it a useful building block in the synthesis of complex molecules with specific functionalities.

Upstream product

• 68884-06-0 2-amino-6-phenylpyrazine-3-carboxylic acid 
• 63211-83-6 7-phenylpteridine 
• 107427-45-2 2-amino-3-formyl-6-phenylpyrazine 
• 33332-28-4 2-amino-6-chloropyrazine 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1300056-92-1 1-[1-(3-diethylaminopropyl)-1H-indol-3-yl]-3-(6-phenylpyrazin-2-yl)urea 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS

Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in onco

HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS

Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in onco

HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS

Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

Iridium-Catalyzed Asymmetric Hydrogenation of Tosylamido-Substituted Pyrazines for Constructing Chiral Tetrahydropyrazines with an Amidine Skelton

Dinuclear triply chloro-bridged iridium(III) complexes bearing chiral diphosphine ligands catalyze the asymmetric hydrogenation of tosylamido-substituted pyrazines to give the corresponding chiral tetrahydropyrazines with an amidine skeleton in high yield and with high enantioselectivity. Addition of N,N-dimethylanilinium bromide enhanced the catalytic activity of the iridium complexes and also increased the enantioselectivity of the products by trapping the hydrogenated amine products with HBr from N,N-dimethylanilinium bromide. The amidine skeleton of the products could be transformed to give chiral piperazinones and piperazines without loss of enantioselectivity. (Figure presented.).

The synthesis and evaluation of indolylureas as PKCα inhibitors

PKCα and PKA have crucial but opposing roles in the regulation of calcium handling within myocytes. Identification of compounds that inhibit PKCα, but not PKA, are potential therapeutic targets for the treatment of heart disease. The synthesis of indolylureas are described, and a compound displaying nanomolar inhibition towards PKCα with significant selectivity over PKA has been identified.

Alkylamination of Pteridines by Primary Alkylamines - Potassium Permanganate

Reaction of 7-phenyl, 7-p-methoxyphenyl, 7-t-butyl- and 6,7-diphenylpteridine with ethylamine and t-butylamine in the presence of potassium permanganate leads to the introduction of the ethylamino or t-butylamino group at C-4 in the above-mentioned pterid